255 related articles for article (PubMed ID: 8893254)
1. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase.
Dasgupta B; King M
Pediatr Pulmonol; 1996 Sep; 22(3):161-6. PubMed ID: 8893254
[TBL] [Abstract][Full Text] [Related]
2. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
King M; Dasgupta B; Tomkiewicz RP; Brown NE
Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
[TBL] [Abstract][Full Text] [Related]
3. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro.
Feng W; Garrett H; Speert DP; King M
Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):710-4. PubMed ID: 9517580
[TBL] [Abstract][Full Text] [Related]
4. Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum.
Sun F; Tai S; Lim T; Baumann U; King M
Can Respir J; 2002; 9(6):401-6. PubMed ID: 12522485
[TBL] [Abstract][Full Text] [Related]
5. Effects of sputum oscillations and rhDNase in vitro: a combined approach to treat cystic fibrosis lung disease.
Dasgupta B; Brown NE; King M
Pediatr Pulmonol; 1998 Oct; 26(4):250-5. PubMed ID: 9811074
[TBL] [Abstract][Full Text] [Related]
6. Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro.
Dasgupta B; Tomkiewicz RP; Boyd WA; Brown NE; King M
Pediatr Pulmonol; 1995 Aug; 20(2):78-82. PubMed ID: 8570306
[TBL] [Abstract][Full Text] [Related]
7. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis.
App EM; Baran D; Dab I; Malfroot A; Coffiner M; Vanderbist F; King M
Eur Respir J; 2002 Feb; 19(2):294-302. PubMed ID: 11866009
[TBL] [Abstract][Full Text] [Related]
8. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
[TBL] [Abstract][Full Text] [Related]
9. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
[TBL] [Abstract][Full Text] [Related]
10. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
11. The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro.
Stern M; Caplen NJ; Browning JE; Griesenbach U; Sorgi F; Huang L; Gruenert DC; Marriot C; Crystal RG; Geddes DM; Alton EW
Gene Ther; 1998 Jan; 5(1):91-8. PubMed ID: 9536269
[TBL] [Abstract][Full Text] [Related]
12. Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions.
Zahm JM; Debordeaux C; Maurer C; Hubert D; Dusser D; Bonnet N; Lazarus RA; Puchelle E
Am J Respir Crit Care Med; 2001 Apr; 163(5):1153-7. PubMed ID: 11316652
[TBL] [Abstract][Full Text] [Related]
13. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
Suri R; Marshall LJ; Wallis C; Metcalfe C; Bush A; Shute JK
Am J Respir Crit Care Med; 2002 Aug; 166(3):352-5. PubMed ID: 12153969
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum.
Griese M; App EM; Duroux A; Burkert A; Schams A
Pulm Pharmacol Ther; 1997; 10(1):21-7. PubMed ID: 9344829
[TBL] [Abstract][Full Text] [Related]
15. [Effect of rhDNase on rheologic properties and transport capacity of mucus in cystic fibrosis].
Puchelle E; Zahm JM
Arch Pediatr; 1995 Jul; 2(7):670-3. PubMed ID: 7663658
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus.
Zahm JM; Girod de Bentzmann S; Deneuville E; Perrot-Minnot C; Dabadie A; Pennaforte F; Roussey M; Shak S; Puchelle E
Eur Respir J; 1995 Mar; 8(3):381-6. PubMed ID: 7789481
[TBL] [Abstract][Full Text] [Related]
17. DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics.
Perks B; Shute JK
Am J Respir Crit Care Med; 2000 Nov; 162(5):1767-72. PubMed ID: 11069810
[TBL] [Abstract][Full Text] [Related]
18. Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis.
Sanders NN; Franckx H; De Boeck K; Haustraete J; De Smedt SC; Demeester J
Thorax; 2006 Nov; 61(11):962-8. PubMed ID: 17071834
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.
Shak S; Capon DJ; Hellmiss R; Marsters SA; Baker CL
Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9188-92. PubMed ID: 2251263
[TBL] [Abstract][Full Text] [Related]
20. Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy: flutter vs autogenic drainage.
App EM; Kieselmann R; Reinhardt D; Lindemann H; Dasgupta B; King M; Brand P
Chest; 1998 Jul; 114(1):171-7. PubMed ID: 9674466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
